Testing Promising Therapies in Refractory MCL
Relapsed/refractory MCL is characterized by frequent chemoresistance and limited treatment options. No standard … Michael Wang, MD, an associate professor at the University of Texas MD Anderson Cancer Center in Houston, presented interim data from a … Read more on Clinical Oncology News
Dallas-Fort Worth Hospitals Responding to the Rising Stakes in Patient …
Texas Health Resources has had a vice president of service excellence since 2010. In June, more than 100 … In October, the Centers for Medicare and Medicaid Services began withholding 1 percent of hospital reimbursement to be redistributed as … Read more on D Healthcare Daily
Mirati Therapeutics Appoints Isan Chen as Chief Medical and Development …
In addition, he was the clinical lead for sunitinib, a multiple kinase inhibitor for the treatment of renal cell carcinoma, an indication in which the drug secured FDA approval in 2006. Before joining Pfizer, Dr. Chen practiced medicine as a staff … Read more on DigitalJournal.com